Amneal Pharmaceuticals

Today, we announced two advancements within our specialty and generic pipelines. First in specialty, the resubmission of the new drug application (NDA) for our dihydroergotamine (DHE) prefilled syringe autoinjector for the acute treatment of migraine with or without aura and cluster headache in adults.?Second in generics, we received U.S.FDA Approval for exenatide, our first generic injectable glucagon-like peptide-1 (GLP-1) agonist, reflecting our innovation capabilities in peptide development and drug-device combinations. Learn more: https://lnkd.in/dMWayyRR

We are a leader in complex, high-quality medicines and we are committed to maintaining that position by cultivating talent and fostering a culture of ongoing learning. Reflecting on these efforts, we are excited to announce the successful launch of the third batch with 30 new members of our Amneal team for the Sterile Manufacturing course, under our AmNeev learning initiative. This course offers a unique blend of theoretical learning and hands-on experience, ensuring participants are industry-ready by the time they complete the program. During the launch, our Amneal leaders highlighted how this course is designed to meet the growing needs of sterile manufacturing by training professionals with the specialized skills required for this evolving field. We are also proud to share that the first two batches, comprising 60 members, are close to completing their training and will soon join the Amneal workforce in their entirety. Here's to building a stronger, more capable workforce together!

The U.S. FDA has awarded Amneal more Competitive Generic Therapy (CGT) product approvals than any other company since the FDA created the approval pathway. CGT designation is given when there is inadequate generic competition on the market for a specific drug. https://lnkd.in/dzfSDqp9?(Accessed November 19, 2024)

Watch Srinivas’ Voices of Leadership video here: https://lnkd.in/e7-vXha5

What enables us to make healthy possible? Is it the innovation in our labs, our reputation for world class research and quality, is it our obsession with delivering affordable medicines, or is it us? The answer is all of it. Important note - Amneal has three reportable business segments: 1) Generics (includes retail, injectables, biosimilars & international revenue), 2) Specialty and 3) AvKARE (includes distribution, government label and institutional revenue).

It’s #GlobalBiosimilarsWeek! This year's campaign is focused on advancing access to biosimilars- a commitment that our team is focused on every day.? Learn more: https://lnkd.in/d_cpUnQ

On behalf of our 7,800 global team members, we announced strong third quarter results today, including broad-based revenue growth across all three of our business segments: Generics, Specialty and AvKARE. As we execute our strategy, further diversify, and drive sustainable growth, we are building Amneal as a leading, diversified global pharmaceutical company. Please reference Amneal’s Third Quarter press release for more information, including non-GAAP financial measures, reconciliations and risks related to forward-looking statements: https://lnkd.in/ehZfceJz

We make high quality medicines more accessible, from our family to yours. Learn more: Amneal.com

Teamwork. Gratitude. How we can make healthy possible for many more people.?These were just a few of the topics discussed at our global leadership meeting earlier this month in Long Branch, New Jersey. And, in true Amneal fashion, we also had a little bit of fun!

Join a culture where innovation and quality fuel our purpose: Amneal.com/careers Some of our newest Endocrinology commercial team members just joined us in Bridgewater, New Jersey!